Alzheimer’s disease (AD) is the most common form of dementia. Although AD is one of the most socioeconomically devastating diseases confronting humanity, no “curative” disease modifying drug has been identified. Recent decades have witnessed repeated failures of drug trials and have called into question the utility of the amyloid hypothesis approach to AD therapeutics design. Accordingly, new neurochemical processes are being evaluated and explored as sources of alternative druggable targets. Among these newly identified targets, neuroinflammation is emerging as a front-runner, and within the realm of neuroinflammation, the inflammasome, particularly the NLRP3 complex, is garnering focussed attention. This review summarizes current data and approaches to understanding the role of the NLRP3 inflammasome in neuroinflammation and AD, and systematically identifies and evaluates multiple targets within the NLRP3 inflammasome cascade as putative drug targets.
ChunH, MarriottI, LeeCJ, ChoH (2018) Elucidating the interactive roles of glia in Alzheimer’s disease using established and newly developed experimental models. Front Neurol9, 797.
12.
YangY, WangH, KouadirM, SongH, ShiF (2019) Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis10, 128.
FranchiL, EigenbrodT, Munoz-PlanilloR, NunezG (2009) The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol10, 241–247.
15.
HenekaMT, KummerMP, StutzA, DelekateA, SchwartzS, Vieira-SaeckerA, GriepA, AxtD, RemusA, TzengTC, GelpiE, HalleA, KorteM, LatzE, GolenbockDT (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature493, 674–678.
16.
ZahidA, LiB, KombeAJK, JinT, TaoJ (2019) Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol10, 2538.
BaliJ, GheinaniAH, ZurbriggenS, RajendranL (2012) Role of genes linked to sporadic Alzheimer’s disease risk in the production of beta-amyloid peptides. Proc Natl Acad Sci U S A109, 15307–15311.
FratiglioniL, AhlbomA, ViitanenM, WinbladB (1993) Risk factors for late-onset Alzheimer’s disease: A population-based, case-control study. Ann Neurol33, 258–266.
21.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
22.
PugazhenthiS, QinL, ReddyPH (2017) Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis1863, 1037–1045.
23.
CastellaniRJ, PerryG (2012) Pathogenesis and disease-modifying therapy in Alzheimer’s disease: The flat line of progress. Arch Med Res43, 694–698.
24.
Mullard A (2019) Anti-amyloid failures stack up as Alzheimer antibody flops. Nat Rev Drug Discov18, 327.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
27.
GiacobiniE, GoldG (2013) Alzheimer disease therapy–moving from amyloid-beta to tau.. Nat Rev Neurol9, 677–686.
28.
GuillozetAL, WeintraubS, MashDC, MesulamMM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol60, 729–736.
29.
SantacruzK, LewisJ, SpiresT, PaulsonJ, KotilinekL, IngelssonM, GuimaraesA, DeTureM, RamsdenM, McGowanE, ForsterC, YueM, OrneJ, JanusC, MariashA, KuskowskiM, HymanB, HuttonM, AsheKH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science309, 476–481.
30.
AndorferC, AckerCM, KressY, HofPR, DuffK, DaviesP (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci25, 5446–5454.
31.
WittmannCW, WszolekMF, ShulmanJM, SalvaterraPM, LewisJ, HuttonM, FeanyMB (2001) Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science293, 711–714.
32.
WardSM, HimmelsteinDS, LanciaJK, BinderLI (2012) Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans40, 667–671.
33.
OzbenT, OzbenS (2019) Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem72, 87–89.
34.
JiK, AkgulG, WollmuthLP, TsirkaSE (2013) Microglia actively regulate the number of functional synapses. PLoS One8, e56293.
35.
NimmerjahnA, KirchhoffF, HelmchenF (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma. Science308, 1314–1318.
Mandrekar-ColucciS, LandrethGE (2010) Microglia and inflammation in Alzheimer’s disease. CNS Neurol Disord Drug Targets9, 156–167.
38.
LucinKM, Wyss-CorayT (2009) Immune activation in brain aging and neurodegeneration: Too much or too little?Neuron64, 110–122.
39.
HenekaMT, McManusRM, LatzE (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci19, 610–621.
40.
RansohoffRM (2016) How neuroinflammation contributes to neurodegeneration. Science353, 777–783.
41.
MantovaniA, SicaA, SozzaniS, AllavenaP, VecchiA, LocatiM (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol25, 677–686.
42.
HalleA, HornungV, PetzoldGC, StewartCR, MonksBG, ReinheckelT, FitzgeraldKA, LatzE, MooreKJ, GolenbockDT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol9, 857–865.
43.
TakeuchiO, AkiraS (2010) Pattern recognition receptors and inflammation. Cell140, 805–820.
44.
WalshJG, MuruveDA, PowerC (2014) Inflammasomes in the CNS. Nat Rev Neurosci15, 84–97.
45.
ThawkarBS, KaurG (2019) Inhibitors of NF-kappaB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease.. J Neuroimmunol326, 62–74.
46.
KelleyN, JeltemaD, DuanY, HeY (2019) The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci20, 3328.
47.
SaresellaM, La RosaF, PianconeF, ZoppisM, MarventanoI, CalabreseE, RainoneV, NemniR, MancusoR, ClericiM (2016) The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol Neurodegener11, 23.
48.
GriffinWS, StanleyLC, LingC, WhiteL, MacLeodV, PerrotLJ, WhiteCL, 3rd, AraozC (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A86, 7611–7615.
49.
ShaftelSS, GriffinWS, O’BanionMK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J Neuroinflammation5, 7.
50.
Blum-DegenD, MullerT, KuhnW, GerlachM, PrzuntekH, RiedererP (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett202, 17–20.
51.
WangS, YuanYH, ChenNH, WangHB (2019) The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol67, 458–464.
52.
LiuH, XuR, KongQ, LiuJ, YuZ, ZhaoC (2017) Downregulated NLRP3 and NLRP1 inflammasomes signaling pathways in the development and progression of type 1 diabetes mellitus. Biomed Pharmacother94, 619–626.
53.
OlcumM, TastanB, KiserC, GencS, GencK (2020) Microglial NLRP3 inflammasome activation in multiple sclerosis. Adv Protein Chem Struct Biol119, 247–308.
ZhangY, ZhaoY, ZhangJ, YangG (2020) Mechanisms of NLRP3 inflammasome activation: Its role in the treatment of Alzheimer’s disease. Neurochem Res45, 2560–2572.
56.
Munoz-PlanilloR, KuffaP, Martinez-ColonG, SmithBL, RajendiranTM, NunezG (2013) K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity38, 1142–1153.
SanmanLE, QianY, EiseleNA, NgTM, van der LindenWA, MonackDM, WeerapanaE, BogyoM (2016) Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death.. Elife5, e13663.
OjalaJ, AlafuzoffI, HerukkaSK, van GroenT, TanilaH, PirttilaT (2009) Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging30, 198–209.
65.
MottaM, ImbesiR, Di RosaM, StivalaF, MalaguarneraL (2007) Altered plasma cytokine levels in Alzheimer’s disease: Correlation with the disease progression. Immunol Lett114, 46–51.
66.
StancuIC, CremersN, VanrusseltH, CouturierJ, VanoosthuyseA, KesselsS, LodderC, BroneB, HuauxF, OctaveJN, TerwelD, DewachterI (2019) Aggregated tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology. Acta Neuropathol137, 599–617.
WangDB, DaytonRD, ZweigRM, KleinRL (2010) Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response. Exp Neurol224, 197–206.
69.
KleinRL, DaytonRD, DiaczynskyCG, WangDB (2010) Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging31, 2091–2102.
70.
PomplPN, YemulS, XiangZ, HoL, HaroutunianV, PurohitD, MohsR, PasinettiGM (2003) Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch Neurol60, 369–376.
71.
FloresJ, NoelA, FoveauB, LynhamJ, LecruxC, LeBlancAC (2018) Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. Nat Commun9, 3916.
72.
MartinonF, BurnsK, TschoppJ (2002) The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell10, 417–426.
73.
VoetS, SrinivasanS, LamkanfiM, vanLoo G (2019) Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med11, e10248.
74.
MalikA, KannegantiTD (2017) Inflammasome activation and assembly at a glance. J Cell Sci130, 3955–3963.
75.
WrightAL, ZinnR, HohensinnB, KonenLM, BeynonSB, TanRP, ClarkIA, AbdipranotoA, VisselB (2013) Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One8, e59586.
76.
DinarelloCA, SimonA, van der MeerJW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov11, 633–652.
77.
HigashimoriA, WatanabeT, NadataniY, TakedaS, OtaniK, TanigawaT, YamagamiH, ShibaM, TominagaK, FujiwaraY, ArakawaT (2016) Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy. Mucosal Immunol9, 659–668.
Ruiz-RuizC, Garcia-MagroN, NegredoP, AvendanoC, BhattacharyaA, CeustersM, GarciaAG (2020) Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1(G93A) female mice. Dis Model Mech13, dmm045732.
80.
MurphyN, CowleyTR, RichardsonJC, VirleyD, UptonN, WalterD, LynchMA (2012) The neuroprotective effect of a specific P2X(7) receptor antagonist derives from its ability to inhibit assembly of the NLRP3 inflammasome in glial cells. Brain Pathol22, 295–306.
81.
KhammyMM, KimS, BentzenBH, LeeS, ChoiI, AalkjaerC, JeppsTA (2018) 4-Aminopyridine: A pan voltage-gated potassium channel inhibitor that enhances Kv 7.4 currents and inhibits noradrenaline-mediated contraction of rat mesenteric small arteries. Br J Pharmacol175, 501–516.
US National Library of Medicine, High Doses of 4- aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients. https://clinicaltrials.gov/ct2/show/NCT03899584, Last updated February 21, 2021, Accessed on June 2, 2021.
85.
GrimaldiA, D’AlessandroG, Di CastroMA, LauroC, SinghV, PaganiF, SfornaL, GrassiF, Di AngelantonioS, CatacuzzenoL, WulffH, LimatolaC, CatalanoM (2018) Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Sci Rep8, 7654.
86.
MeiY, FangC, DingS, LiuX, HuJ, XuJ, MeiQ (2019) PAP-1 ameliorates DSS-induced colitis with involvement of NLRP3 inflammasome pathway. Int Immunopharmacol75, 105776.
87.
RehmanAU, DugicE, BenhamC, LioneL, MackenzieLS (2014) Selective inhibition of NADPH oxidase reverses the over contraction of diabetic rat aorta. Redox Biol2, 61–64.
88.
JoshiS, KhanSR (2019) NADPH oxidase: A therapeutic target for hyperoxaluria-induced oxidative stress - an update. Future Med Chem11, 2975–2978.
MaMW, WangJ, DhandapaniKM, BrannDW (2017) NADPH oxidase 2 regulates NLRP3 inflammasome activation in the brain after traumatic brain injury. Oxid Med Cell Longev2017, 6057609.
91.
PiippoN, KorhonenE, HyttiM, KinnunenK, KaarnirantaK, KauppinenA (2018) Oxidative stress is the principal contributor to inflammasome activation in retinal pigment epithelium cells with defunct proteasomes and autophagy. Cell Physiol Biochem49, 359–367.
92.
HookG, JacobsenJS, GrabsteinK, KindyM, HookV (2015) Cathepsin B is a new drug target for traumatic brain injury therapeutics: Evidence for E64d as a promising lead drug candidate. Front Neurol6, 178.
93.
GaoRF, LiX, XiangHY, YangH, LvCY, SunXL, ChenHZ, GaoY, YangJS, LuoW, YangYQ, TangYH (2021) The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol90, 107133.
94.
DingY, DingC, YeN, LiuZ, WoldEA, ChenH, WildC, ShenQ, ZhouJ (2016) Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem122, 102–117.
95.
PereraAP, FernandoR, ShindeT, GundamarajuR, SouthamB, SohalSS, RobertsonAAB, SchroderK, KundeD, EriR (2018) MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep8, 8618.
[97 SAME AS 141], LonnemannN, HosseiniS, MarchettiC, SkourasDB, StefanoniD, D’AlessandroA, DinarelloCA, KorteM (2020) The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A117, 32145–32154.
98.
JansenTL, KlückV, JanssenM, ComarniceanuA, EfdéM, ScribnerCL, BarrowRB, SkourasDB, DinarelloCA, JoostenLA (2019) P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrileTM (Otive NLRP3 inflammasome inhibitor, dapansutrileTM (OLT1177TM), in acute gout. Ann Rheum Dis78, A70–71.
SaraghiM, HershEV (2013) Three newly approved analgesics: An update. Anesth Prog60, 178–187.
101.
KuwarR, RolfeA, DiL, XuH, HeL, JiangY, ZhangS, SunD (2019) A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation16, 81.
102.
McKenzieBA, MamikMK, SaitoLB, BoghozianR, MonacoMC, MajorEO, LuJQ, BrantonWG, PowerC (2018) Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc Natl Acad Sci U S A115, E6065–E6074.
103.
US National Library of Medicine, A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects withTreatment- Resistant Partial Epilepsy. https://clinicaltrials.gov/ct2/show/NCT01501383, Last updated September 30, 2020, Accessed on June 2, 2021.
104.
LinX, YeH, Siaw-DebrahF, PanS, HeZ, NiH, XuZ, JinK, ZhugeQ, HuangL (2018) AC-YVAD-CMK inhibits pyroptosis and improves functional outcome after intracerebral hemorrhage. Biomed Res Int2018, 3706047.
105.
ZhangF, WangL, WangJJ, LuoPF, WangXT, XiaZF (2016) The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: Involvement of silencing NLRP3 inflammasome activities. Sci Rep6, 24166.
US National Library of Medicine, β-hydroxybutyrate, Glucose Metabolism and Prediabetes (CETUS). https://clinicaltrials.gov/ct2/show/NCT03889210, Last updated November 6, 2019, Accessed on June 2, 2021.
108.
MartinE, AmarM, DalleC, YoussefI, BoucherC, Le DuigouC, BrucknerM, PrigentA, SazdovitchV, HalleA, KanellopoulosJM, FontaineB, DelatourB, DelarasseC (2019) New role of P2X7 receptor in an Alzheimer’s disease mouse model. Mol Psychiatry24, 108–125.
109.
SanzJM, ChiozziP, FerrariD, ColaiannaM, IdzkoM, FalzoniS, FellinR, TrabaceL, Di VirgilioF (2009) Activation of microglia by amyloid beta requires P2X7 receptor expression. J Immunol182, 4378–4385.
110.
FiebichBL, AkterS, AkundiRS (2014) The two-hit hypothesis for neuroinflammation: Role of exogenous ATP in modulating inflammation in the brain. Front Cell Neurosci8, 260.
111.
RiteauN, BaronL, VilleretB, GuillouN, SavignyF, RyffelB, RassendrenF, Le BertM, GombaultA, CouillinI (2012) ATP release and purinergic signaling: A common pathway for particle-mediated inflammasome activation. Cell Death Dis3, e403.
112.
FerrariD, PizziraniC, AdinolfiE, LemoliRM, CurtiA, IdzkoM, PantherE, Di VirgilioF (2006) The P2X7 receptor: A key player in IL-1 processing and release. J Immunol176, 3877–3883.
113.
SuzukiT, HideI, IdoK, KohsakaS, InoueK, NakataY (2004) Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci24, 1–7.
114.
TakenouchiT, IwamaruY, SugamaS, SatoM, HashimotoM, KitaniH (2008) Lysophospholipids and ATP mutually suppress maturation and release of IL-1 beta in mouse microglial cells using a Rho-dependent pathway. J Immunol180, 7827–7839.
115.
BaricordiOR, MelchiorriL, AdinolfiE, FalzoniS, ChiozziP, BuellG, Di VirgilioF (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem274, 33206–33208.
116.
FerrariD, ChiozziP, FalzoniS, Dal SusinoM, ColloG, BuellG, Di VirgilioF (1997) ATP-mediated cytotoxicity in microglial cells. Neuropharmacology36, 1295–1301.
117.
ParvathenaniLK, TertyshnikovaS, GrecoCR, RobertsSB, RobertsonB, PosmanturR (2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease. J Biol Chem278, 13309–13317.
118.
LeeHG, WonSM, GwagBJ, LeeYB (2011) Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Exp Mol Med43, 7–14.
119.
JinH, HanJ, ResingD, LiuH, YueX, MillerRL, SchochKM, MillerTM, PerlmutterJS, EganTM, TuZ (2018) Synthesis andcharacterization of a P2X7 radioligand [(123)I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease. Eur J Pharmacol820, 8–17.
120.
McLarnonJG, RyuJK, WalkerDG, ChoiHB (2006) Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol65, 1090–1097.
121.
LaurentC, DorotheeG, HunotS, MartinE, MonnetY, DuchampM, DongY, LegeronFP, LeboucherA, BurnoufS, FaivreE, CarvalhoK, CaillierezR, ZommerN, DemeyerD, JouyN, SazdovitchV, Schraen-MaschkeS, DelarasseC, BueeL, BlumD (2017) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain140, 184–200.
122.
RyuJK, McLarnonJG (2008) Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer’s disease. Neuroreport19, 1715–1719.
123.
Diaz-HernandezJI, Gomez-VillafuertesR, Leon-OteguiM, Hontecillas-PrietoL, Del PuertoA, TrejoJL, LucasJJ, GarridoJJ, GualixJ, Miras-PortugalMT, Diaz-HernandezM (2012) In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3beta and secretases. Neurobiol Aging33, 1816–1828.
124.
FerrazoliEG, de SouzaHD, NascimentoIC, Oliveira-GiacomelliA, SchwindtTT, BrittoLR, UlrichH (2017) Brilliant blue G, but not fenofibrate, treatment reverts hemiparkinsonian behavior and restores dopamine levels in an animal model of Parkinson’s disease. Cell Transplant26, 669–677.
RangarajuS, GearingM, JinLW, LeveyA (2015) Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer’s disease. J Alzheimers Dis44, 797–808.
127.
MaezawaI, NguyenHM, Di LucenteJ, JenkinsDP, SinghV, HiltS, KimK, RangarajuS, LeveyAI, WulffH, JinLW (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: Preclinical proof of concept. Brain141, 596–612.
128.
FranciosiS, RyuJK, ChoiHB, RadovL, KimSU, McLarnonJG (2006) Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. J Neurosci26, 11652–11664.
129.
SchillingT, EderC (2011) Amyloid-beta-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J Cell Physiol226, 3295–3302.
130.
MariathasanS, WeissDS, NewtonK, McBrideJ, O’RourkeK, Roose-GirmaM, LeeWP, WeinrauchY, MonackDM, DixitVM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature440, 228–232.
131.
HornungV, BauernfeindF, HalleA, SamstadEO, KonoH, RockKL, FitzgeraldKA, LatzE (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol9, 847–856.
132.
AlvesLA, de Melo ReisRA, de SouzaCA, de FreitasMS, TeixeiraPC, Neto Moreira FerreiraD, XavierRF (2014) The P2X7 receptor: Shifting from a low- to a high-conductance channel - an enigmatic phenomenon?Biochim Biophys Acta1838, 2578–2587.
133.
GreaneyAJ, LepplaSH, MoayeriM (2015) Bacterial exotoxins and the inflammasome. Front Immunol6, 570.
134.
MadryC, KyrargyriV, Arancibia-CarcamoIL, JolivetR, KohsakaS, BryanRM, AttwellD (2018) Microglial ramification, surveillance, and interleukin-1beta release are regulated by the two-pore domain K(+) Channel THIK-1. Neuron97, 299–312e296.
135.
ButterfieldDA, SwomleyAM, SultanaR (2013) Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal19, 823–835.
136.
HuangWJ, ZhangX, ChenWW (2016) Role of oxidative stress in Alzheimer’s disease. Biomed Rep4, 519–522.
137.
JalbertJJ, DaielloLA, LapaneKL (2008) Dementia of the Alzheimer type. Epidemiol Rev30, 15–34.
138.
SanzA, StefanatosRK (2008) The mitochondrial free radical theory of aging: A critical view. Curr Aging Sci1, 10–21.
139.
LullME, BlockML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics7, 354–365.
140.
KadowakiH, NishitohH, UranoF, SadamitsuC, MatsuzawaA, TakedaK, MasutaniH, YodoiJ, UranoY, NaganoT, IchijoH (2005) Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ12, 19–24.
141.
MaoP, ReddyPH (2011) Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: Implications for early intervention and therapeutics. Biochim Biophys Acta1812, 1359–1370.
142.
LeeGS, SubramanianN, KimAI, AksentijevichI, Goldbach-ManskyR, SacksDB, GermainRN, KastnerDL, ChaeJJ (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+and cAMP. Nature492, 123–127.
143.
AminzadehM, RoghaniM, SarfallahA, RiaziGH (2018) TRPM2 dependence of ROS-induced NLRP3 activation in Alzheimer’s disease. Int Immunopharmacol54, 78–85.
144.
QinL, LiuY, CooperC, LiuB, WilsonB, HongJS (2002) Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem83, 973–983.
145.
ten FreyhausH, HuntgeburthM, WinglerK, SchnitkerJ, BaumerAT, VantlerM, BekhiteMM, WartenbergM, SauerH, RosenkranzS (2006) Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res71, 331–341.
146.
GrossO, PoeckH, BscheiderM, DostertC, HannesschlagerN, EndresS, HartmannG, TardivelA, SchweighofferE, TybulewiczV, MocsaiA, TschoppJ, RulandJ (2009) Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature459, 433–436.
BaiH, YangB, YuW, XiaoY, YuD, ZhangQ (2018) Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. Exp Cell Res362, 180–187.
149.
ZhaoY, ZhaoB (2013) Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev2013, 316523.
150.
KindyMS, YuJ, ZhuH, El-AmouriSS, HookV, HookGR (2012) Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer’s disease mouse model expressing AbetaPP containing the wild-type beta-secretase site sequence. J Alzheimers Dis29, 827–840.
151.
HookVY, KindyM, HookG (2008) Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem283, 7745–7753.
152.
HookG, HookV, KindyM (2011) The cysteine protease inhibitor, E64d, reduces brain amyloid-beta and improves memory deficits in Alzheimer’s disease animal models by inhibiting cathepsin B, but not BACE1, beta-secretase activity. J Alzheimers Dis26, 387–408.
XuJ, WoldEA, DingY, ShenQ, ZhouJ (2018) Therapeutic potential of oridonin and its analogs: From anticancer and antiinflammation to neuroprotection. Molecules23, 474.
159.
HeH, JiangH, ChenY, YeJ, WangA, WangC, LiuQ, LiangG, DengX, JiangW, ZhouR (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun9, 2550.
WangS, YuL, YangH, LiC, HuiZ, XuY, ZhuX (2016) Oridonin attenuates synaptic loss and cognitive deficits in an Abeta1-42-induced mouse model of Alzheimer’s disease. PLoS One11, e0151397.
162.
SinghJ, PetterRC, BaillieTA, WhittyA (2011) The resurgence of covalent drugs. Nat Rev Drug Discov10, 307–317.
163.
BauerRA (2015) Covalent inhibitors in drug discovery: From accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today20, 1061–1073.
164.
IsmaelS, NasoohiS, IshratT (2018) MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. J Neurotrauma35, 1294–1303.
165.
XuX, YinD, RenH, GaoW, LiF, SunD, WuY, ZhouS, LyuL, YangM, XiongJ, HanL, JiangR, ZhangJ (2018) Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury. Neurobiol Dis117, 15–27.
166.
HullC, DekeryteR, BuchananH, Kamli-SalinoS, RobertsonA, DelibegovicM, PlattB (2020) NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia. Neuropharmacology180, 108305.
167.
DempseyC, Rubio AraizA, BrysonKJ, FinucaneO, LarkinC, MillsEL, RobertsonAAB, CooperMA, O’NeillLAJ, LynchMA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav Immun61, 306–316.
168.
QiY, KlyubinI, CuelloAC, RowanMJ (2018) NLRP3-dependent synaptic plasticity deficit in an Alzheimer’s disease amyloidosis model. Neurobiol Dis114, 24–30.
169.
MullardA (2020) Roche snaps up another NLRP3 contender. Nat Rev Drug Discov19, 744.
170.
MarchettiC, SwartzwelterB, GamboniF, NeffCP, RichterK, AzamT, CartaS, TengesdalI, NemkovT, D’AlessandroA, HenryC, JonesGS, GoodrichSA, St LaurentJP, JonesTM, ScribnerCL, BarrowRB, AltmanRD, SkourasDB, GattornoM, GrauV, JanciauskieneS, RubartelliA, JoostenLAB, DinarelloCA (2018) OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A115, E1530–E1539.
171.
JankowskyJL, FadaleDJ, AndersonJ, XuGM, GonzalesV, JenkinsNA, CopelandNG, LeeMK, YounkinLH, WagnerSL, YounkinSG, BorcheltDR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet13, 159–170.
172.
StuveO, WeidemanRA, McMahanDM, JacobDA, LittleBB (2020) Diclofenac reduces the risk of Alzheimer’s disease: A pilot analysis of NSAIDs in two US veteran populations. Ther Adv Neurol Disord13, 1756286420935676.
173.
MarchettiC, ToldoS, ChojnackiJ, MezzaromaE, LiuK, SalloumFN, NordioA, CarboneS, MauroAG, DasA, ZalavadiaAA, HalquistMS, FedericiM, Van TassellBW, ZhangS, AbbateA (2015) Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse. J Cardiovasc Pharmacol66, 1–8.
174.
YinJ, ZhaoF, ChojnackiJE, FulpJ, KleinWL, ZhangS, ZhuX (2018) NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease. Mol Neurobiol55, 1977–1987.
175.
FranklinBS, BossallerL, De NardoD, RatterJM, StutzA, EngelsG, BrenkerC, NordhoffM, MirandolaSR, Al-AmoudiA, ManganMS, ZimmerS, MonksBG, FrickeM, SchmidtRE, EspevikT, JonesB, JarnickiAG, HansbroPM, BustoP, Marshak-RothsteinA, HornemannS, AguzziA, KastenmullerW, LatzE (2014) The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol15, 727–737.
176.
FrikerLL, ScheiblichH, HochheiserIV, BrinkschulteR, RiedelD, LatzE, GeyerM, HenekaMT (2020) beta-amyloid clustering around ASC fibrils boosts its toxicity in microglia. Cell Rep30, 3743–3754e3746.
177.
SchroderK, TschoppJ (2010) The inflammasomes. Cell140, 821–832.
178.
FuQ, WuJ, ZhouXY, JiMH, MaoQH, LiQ, ZongMM, ZhouZQ, YangJJ (2019) NLRP3/caspase-1 pathway-induced pyroptosis mediated cognitive deficits in a mouse model of sepsis-associated encephalopathy. Inflammation42, 306–318.
179.
LiP, AllenH, BanerjeeS, FranklinS, HerzogL, JohnstonC, McDowellJ, PaskindM, RodmanL, SalfeldJ, TowneE, TraveyD, WardwllS, WeiFY, WongW, KamenR, SeshadriT (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell80, 401–411.
180.
FloresJ, NoelA, FoveauB, BeauchetO, LeBlancAC (2020) Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun11, 4571.
181.
LiangH, SunY, GaoA, ZhangN, JiaY, YangS, NaM, LiuH, ChengX, FangX, MaW, ZhangX, WangF (2019) Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats. Int Immunopharmacol75, 105771.
182.
MaoZ, LiuC, JiS, YangQ, YeH, HanH, XueZ (2017) The NLRP3 inflammasome is involved in the pathogenesis of Parkinson’s disease in rats. Neurochem Res42, 1104–1115.
183.
GemmaC, BachstetterAD, ColeMJ, FisterM, HudsonC, BickfordPC (2007) Blockade of caspase-1 increases neurogenesis in the aged hippocampus. Eur J Neurosci26, 2795–2803.
184.
GemmaC, FisterM, HudsonC, BickfordPC (2005) Improvement of memory for context by inhibition of caspase-1 in aged rats. Eur J Neurosci22, 1751–1756.
DoiY, MizunoT, MakiY, JinS, MizoguchiH, IkeyamaM, DoiM, MichikawaM, TakeuchiH, SuzumuraA (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta neurotoxicity in in vitro and in vivo models of Alzheimer’s disease. Am J Pathol175, 2121–2132.
187.
MichaudJP, HalleM, LampronA, TheriaultP, PrefontaineP, FilaliM, Tribout-JoverP, LanteigneAM, JodoinR, CluffC, BrichardV, PalmantierR, PilorgetA, LarocqueD, RivestS (2013) Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology. Proc Natl Acad Sci U S A110, 1941–1946.
188.
ScholtzovaH, DoE, DhakalS, SunY, LiuS, MehtaPD, WisniewskiT (2017) Innate immunity stimulation via toll-like receptor 9 ameliorates vascular amyloid pathology in Tg-SwDI mice with associated cognitive benefits. J Neurosci37, 936–959.
